RENO, Nev.--(BUSINESS WIRE)--Lifeline Biotechnologies, Inc. (OTCPK: LBTN) today announced that it is nearing a major breakthrough in the early detection of breast cancer. The new experimental classifying algorithms, the basis for Lifeline’s First Warning System™, demonstrate sensitivity of 100% (the ability to find lesions in the breast) and two additional algorithms documented a specificity (the ability to distinguish benign from cancerous lesions) of 84% and 91% with its new neural network system which is nearing ready for clinical testing on large patient data sets.
